Avenue Biosciences

Executive Summary

Avenue Biosciences, a Finnish pre-clinical biotechnology company founded in 2019, has developed a proprietary protein engineering platform that leverages machine learning and synthetic biology to optimize N-terminal signal peptides. This technology aims to significantly enhance the yield and quality of therapeutic protein production, including difficult-to-express biologics, antibodies, and mRNA-based therapies. The platform addresses a critical bottleneck in biologics manufacturing, potentially reducing costs and improving access to complex therapeutics. As a private, early-stage company, Avenue is focused on advancing its platform through proof-of-concept studies and securing partnerships or funding to progress toward preclinical development. The company operates in the ophthalmology category, though its platform is broadly applicable across multiple therapeutic areas. With its innovative approach and strong scientific foundation, Avenue Biosciences is well-positioned to attract investment and collaboration opportunities as it moves toward validating its technology in vivo.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Round60% success
• Q4 2026Licensing or Partnership Deal with Major Pharma40% success
• Q2 2026Publication of Proof-of-Concept In Vivo Data70% success